How European primary care practitioners think the timeliness of cancer diagnosis can be improved: a thematic analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
24 09 2019
Historique:
entrez: 26 9 2019
pubmed: 26 9 2019
medline: 21 10 2020
Statut: epublish

Résumé

National European cancer survival rates vary widely. Prolonged diagnostic intervals are thought to be a key factor in explaining these variations. Primary care practitioners (PCPs) frequently play a crucial role during initial cancer diagnosis; their knowledge could be used to improve the planning of more effective approaches to earlier cancer diagnosis. This study sought the views of PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved. In an online survey, a final open-ended question asked PCPs how they thought the speed of diagnosis of cancer in primary care could be improved. Thematic analysis was used to analyse the data. A primary care study, with participating centres in 20 European countries. A total of 1352 PCPs answered the final survey question, with a median of 48 per country. The main themes identified were: patient-related factors, including health education; care provider-related factors, including continuing medical education; improving communication and interprofessional partnership, particularly between primary and secondary care; factors relating to health system organisation and policies, including improving access to healthcare; easier primary care access to diagnostic tests; and use of information technology. Re-allocation of funding to support timely diagnosis was seen as an issue affecting all of these. To achieve more timely cancer diagnosis, health systems need to facilitate earlier patient presentation through education and better access to care, have well-educated clinicians with good access to investigations and better information technology, and adequate primary care cancer diagnostic pathway funding.

Sections du résumé

BACKGROUND
National European cancer survival rates vary widely. Prolonged diagnostic intervals are thought to be a key factor in explaining these variations. Primary care practitioners (PCPs) frequently play a crucial role during initial cancer diagnosis; their knowledge could be used to improve the planning of more effective approaches to earlier cancer diagnosis.
OBJECTIVES
This study sought the views of PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.
DESIGN
In an online survey, a final open-ended question asked PCPs how they thought the speed of diagnosis of cancer in primary care could be improved. Thematic analysis was used to analyse the data.
SETTING
A primary care study, with participating centres in 20 European countries.
PARTICIPANTS
A total of 1352 PCPs answered the final survey question, with a median of 48 per country.
RESULTS
The main themes identified were: patient-related factors, including health education; care provider-related factors, including continuing medical education; improving communication and interprofessional partnership, particularly between primary and secondary care; factors relating to health system organisation and policies, including improving access to healthcare; easier primary care access to diagnostic tests; and use of information technology. Re-allocation of funding to support timely diagnosis was seen as an issue affecting all of these.
CONCLUSIONS
To achieve more timely cancer diagnosis, health systems need to facilitate earlier patient presentation through education and better access to care, have well-educated clinicians with good access to investigations and better information technology, and adequate primary care cancer diagnostic pathway funding.

Identifiants

pubmed: 31551382
pii: bmjopen-2019-030169
doi: 10.1136/bmjopen-2019-030169
pmc: PMC6773305
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e030169

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Br J Gen Pract. 2014 Nov;64(628):e728-34
pubmed: 25348997
Ir Med J. 2007 Nov-Dec;100(10):624-6
pubmed: 18277732
J Clin Oncol. 2012 Dec 20;30(36):4493-500
pubmed: 23169521
Br J Cancer. 2009 Dec 3;101 Suppl 2:S110-4
pubmed: 19956154
J Gynecol Oncol. 2015 Oct;26(4):262-9
pubmed: 26404122
BMJ Open. 2014 Jun 12;4(6):e004820
pubmed: 24928585
BMC Cancer. 2019 Jan 8;19(1):25
pubmed: 30621616
J Glob Health. 2016 Dec;6(2):020901
pubmed: 28028437
Br J Cancer. 2015 Feb 17;112(4):676-87
pubmed: 25602963
Acta Oncol. 2013 Jun;52(5):919-32
pubmed: 23581611
Br J Cancer. 2009 Dec 3;101 Suppl 2:S125-9
pubmed: 19956156
BMJ. 2015 Jan 07;350:g7773
pubmed: 25569206
BMC Health Serv Res. 2018 May 8;18(1):338
pubmed: 29739409
Nature. 2001 May 17;411(6835):390-5
pubmed: 11357148
Br J Cancer. 2015 Mar 31;112 Suppl 1:S41-9
pubmed: 25734388
Br J Cancer. 2013 Oct 1;109(7):2014-9
pubmed: 23963144
BMJ. 2011 Jun 09;342:d3399
pubmed: 21659366
BMJ Open. 2015 Sep 14;5(9):e008525
pubmed: 26369800
Int J Cancer. 2016 Aug 1;139(3):607-12
pubmed: 26991033
Thorax. 2013 Jun;68(6):551-64
pubmed: 23399908
Eur J Oncol Nurs. 2018 Jun;34:82-88
pubmed: 29784144
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
Br J Cancer. 1995 Sep;72(3):738-43
pubmed: 7669587
Eur J Cancer. 2013 Jun;49(9):2187-98
pubmed: 23453935
Asian Pac J Cancer Prev. 2013;14(9):4977-82
pubmed: 24175762
Scand J Prim Health Care. 2010 Dec;28(4):249-55
pubmed: 20950124
Br J Gen Pract. 2011 Apr;61(585):173-82
pubmed: 21439175
Health Expect. 2016 Apr;19(2):377-87
pubmed: 25808166
Lung Cancer. 2017 Oct;112:156-164
pubmed: 29191588
BMJ. 1996 May 4;312(7039):1125-8
pubmed: 8620127
J Adv Nurs. 2004 Oct;48(2):175-86
pubmed: 15369498
Br J Gen Pract. 2011 May;61(586):317-8
pubmed: 21619755
Health Policy. 2013 Sep;112(1-2):148-55
pubmed: 23693117
Br J Cancer. 2011 Jul 26;105(3):340-5
pubmed: 21750554
Thorax. 2009 Sep;64(9):749-56
pubmed: 19717709
J Clin Oncol. 2014 Jan 1;32(1):27-33
pubmed: 24276779
Health Soc Care Community. 2012 Nov;20(6):607-16
pubmed: 22804847
Cancer Epidemiol. 2013 Apr;37(2):186-90
pubmed: 23369450
Implement Sci. 2012 Oct 15;7:97
pubmed: 23068016
Ann Oncol. 2012 Oct;23(10):2731-7
pubmed: 22553194
BMJ Open. 2018 Sep 5;8(9):e022904
pubmed: 30185577

Auteurs

Michael Harris (M)

Department for Health, University of Bath, Bath, UK michaelharris681@btinternet.com.
Berner Institut für Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland.

Hans Thulesius (H)

Department of Clinical Sciences, Lund University, Lund, Sweden.
Department of Research and Development, Region Kronoberg, Sweden.

Ana Luísa Neves (AL)

Institute of Global Health Innovation, Imperial College London, London, UK.
CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine, University of Porto, Porto, Portugal.

Sophie Harker (S)

Department for Health, University of Bath, Bath, UK.

Tuomas Koskela (T)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Davorina Petek (D)

Department of Family Medicine, University of Ljubljana, Ljubljana, Slovenia.

Robert Hoffman (R)

Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel.

Mette Brekke (M)

Department of General Practice and General Practice Research Unit, University of Oslo, Oslo, Norway.

Krzysztof Buczkowski (K)

Department of Family Medicine, Nicolaus Copernicus University, Toruń, Poland.

Nicola Buono (N)

Department of General Practice, National Society of Medical Education in General Practice (SNaMID), Caserta, Italy.

Emiliana Costiug (E)

Family Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Geert-Jan Dinant (GJ)

Department of General Practice, Maastricht University, Maastricht, The Netherlands.

Gergana Foreva (G)

Medical Center BROD, Plovdiv, Bulgaria.

Eva Jakob (E)

Primary Health Centre, Centro de Saúde Sarria, Sarria, Lugo, Spain.

Mercè Marzo-Castillejo (M)

Unitat de Suport a la Recerca, IDIAP Jordi Gol, Institut Català de la Salut, Barcelona, Spain.

Peter Murchie (P)

Division of Applied Health Sciences - Academic Primary Care, University of Aberdeen, Aberdeen, UK.

Jolanta Sawicka-Powierza (J)

Department of Family Medicine, Medical University of Bialystok, Bialystok, Poland.

Antonius Schneider (A)

TUM School of Medicine, Institute of General Practice and Health Services Research, Technical University of Munich, München, Germany.

Emmanouil Smyrnakis (E)

Laboratory of Primary Health Care, General Practice and Health Services Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Sven Streit (S)

Berner Institut für Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland.

Gordon Taylor (G)

College of Medicine and Health, University of Exeter, Exeter, UK.

Peter Vedsted (P)

Research Unit for General Practice, Aarhus University, Aarhus, Denmark.

Birgitta Weltermann (B)

Institut für Hausarztmedizin, University of Bonn, Bonn, Germany.

Magdalena Esteva (M)

Research Unit, Majorca Primary Health Care Department, Balearic Islands Health Research Institute (IdISBa), Preventive Activities and Health Promotion Network, Carlos III Institute of Health (RedIAPP-RETICS), Palma de Mallorca, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH